2Prof. Dr., Ondokuz Mayis University, Ophthalmology, Samsun - Türkiye Objective: To assess and compare the effi cacy of intravitreal ranibizumab (IR) and dexamethasone implant (IDI) in eyes with macular edema (ME) secondary to branch and central retinal vein occlusion (BRVO and CRVO).
Material and Methods: This is a retrospective study. Patients who had received IR 0.5mg/0.05mL or IDI 0.7mg for the treatment of ME due to BRVO or CRVO were included in the study. Effi cacy outcomes were considered as the change from baseline in best-corrected visual acuity (BCVA) and central macular thickness (CMT).
Results: Forty three patients were included (24 BRVO, 19 CRVO) in the study. BCVA and CMT improved from baseline in all groups. In BRVO patients, increase of mean BCVA was signifi cantly higher with IR in the 4th, 5th and 6th months, and decrease of mean CMT was signifi cantly higher with IDI only in the 1st month. In CRVO patients, there were not signifi cant differences in BCVA and CMT improvements compared to IR or IDI. The mean number of injections was 2.3 and 2.7 for BRVO and CRVO cases treated with IR, 1.4 and 1.3 for BRVO and CRVO cases treated with IDI in 6 months. Intraocular pressure (IOP) increase occurred in 3(33.3%) BRVO and 1(11.1%) CRVO patients treated with IDI.
Conclusion: Intravitreal ranibizumab and IDI provide signifi cant benefi ts in visual acuity gain and anatomic improvement in eyes with ME secondary to BRVO and CRVO. Ranibizumab seems to be more effective in BCVA gain in BRVO patients. Increase in IOP can be observed in IDI treated patients.
Keywords : Branch retinal vein occlusion, central retinal vein occlusion, dexamethasone implant, ranibizumab, retinal vein occlusion